✦ LIBER ✦

Cutaneous T-Cell Lymphoma: In Response

✍ Scribed by Niewold, Timothy B.; Swaroop, Vege Santhi

Book ID: 123275286
Publisher: Mayo Clinic
Year: 2003
Tongue: English
Weight: 41 KB
Volume: 78
Category: Article
ISSN: 0025-6196
DOI: 10.4065/78.8.1055

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Response rates in photopheresis therapy

Response rates in photopheresis therapy for cutaneous T-cell lymphoma

✍ Zackheim, Herschel S.; Kashani-Sabet, Mohammed 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 216 KB

Extracorporeal photochemotherapy in pati

Extracorporeal photochemotherapy in patients with cutaneous T-cell lymphoma: is clinical response predictable?

✍ V Rao; K Ryggen; M Aarhaug; HY Dai; S Jørstad; T Moen 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB

Predictors of complete responses with de

Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma

✍ Francine Foss; Madeleine Duvic; Elise A. Olsen 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 659 KB

Biologic Correlates of Response and Surv

Biologic Correlates of Response and Survival in Patients with Cutaneous T-Cell Lymphoma Treated with Denileukin Diftitox

✍ Chin, Kevin M.; Foss, Francine M. 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 171 KB

CD25 Expression Is Correlated with Histo

CD25 Expression Is Correlated with Histological Grade and Response to Denileukin Diftitox in Cutaneous T-Cell Lymphoma

✍ Talpur, Rakhshandra; Jones, Daniel M; Alencar, Alvaro J; Apisarnthanarax, Narin; 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 204 KB

DAB389IL2 diphtheria fusion toxin produc

DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma

✍ Duvic, Madeleine; Cather, Jennifer; Maize, John; Frankel, Arthur E. 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Four patients with late stage cutaneous T cell lymphoma (IB-IVA) who had failed at least two previous therapies were treated with DAB 389 IL2 at 9 or 18 µg/kg as 15-min intravenous infusions daily for 5 days every 3 weeks for eight cycles. Mild vascular leak syndrome (VLS) with transient edema, hypo